Medable’s new technology aims to save time by automating manual tasks such as testing and eliminating electronic clinical outcome assessments (eCOAs) from a critical pathway to trial initiation. Featuring new AI and automation capabilities, this technology aims to eliminate common logjams caused by conversion, configuration, validation, and quality engineering.
Medable’s updated eCOA functionality includes an automatic configuration tool that creates standard configurations such as assessment schedules, anchor dates, and patient flags. Medable’s automated validation tools are designed to automatically deliver downloadable Configuration Validation Reports (CVRs) that validate the quality of your research builds.
“We are reimagining how clinical trials are deployed by eliminating many of the biggest bottlenecks in the process,” said Michelle Longmire, CEO and co-founder of Medable. “Starting with eCOA, we are helping to improve data quality while accelerating clinical trials, ultimately allowing studies to begin in one day and delivering effective treatments and cures to patients faster. We are delivering on our vision. In 2024, we expect to see more innovative technologies and new ways to deliver streamlined, patient-centered clinical trials from Medable.”
